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An overview of current practice 
in external beam radiation oncology 
with consideration to potential benefits 
and challenges for nanotechnology
Raymond B. King1,2*, Stephen J. McMahon1, Wendy B. Hyland3, Suneil Jain1,4, Karl T. Butterworth1, 
Kevin M. Prise1, Alan R. Hounsell1,2 and Conor K. McGarry1,2
Background
The past two decades have seen significant advances in the technology employed in the 
radiation oncology environment. These advancements have enabled a move towards 
more individualised radiotherapy treatments, with the aim of improving their quality to 
obtain the optimum clinical outcome for individual patients [e.g. CHHIP clinical trial 
results recently published in Lancet Oncology (Wilkins et al. 2015)]. In the same period, 
research into the use of nanotechnology in medicine has also exploded, with a signifi-
cant number of prospective clinical benefits reported. The potential medical applications 
of nanomaterials are vast and include tissue engineering (Walmsley et al. 2015), protein 
detection (Nam et al. 2003; Agasti et al. 2010) and drug and/or gene delivery (Panyama 
and Labhasetwara 2003; Lin et al. 2015). In addition to these applications, many studies 
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have also proposed the inclusion of nanoparticles (NPs) into both diagnostic and radia-
tion therapy settings, emphasising their use as potential theranostic agents (Sancey et al. 
2014). The purpose of this communication is to provide an overview of the current prac-
tice in the clinical radiation oncology environment and to discuss how recent advances 
in this field may be combined with nanotechnology to further enhance the effectiveness 
of patient’s treatments. We also highlight some potential challenges that may be encoun-
tered as nanotechnology is introduced into the clinical radiation environment.
Cancer imaging diagnostics
Patients may undergo an array of diagnostic imaging examinations as part of their oncol-
ogy pathway, including x-ray computed tomography (CT), magnetic resonance imaging 
(MRI) and radioisotope imaging such as single-photon emission computed tomography 
(SPECT) and positron emission tomography (PET). Each imaging modality provides 
unique diagnostic data and a multimodality approach is often required to obtain the 
necessary information for accurate diagnosis.
CT imaging
A common feature of x-ray-based imaging modalities is the lack of contrast between dif-
ferent types of soft tissue. Radiocontrast agents can be used to overcome this problem, 
utilising the enhanced x-ray attenuation properties of high atomic number (Z) elements 
(typically iodine or barium) to differentiate between tissues and accentuate additional 
anatomical detail, such as vascular tissue. With each evolution in CT design, there has 
typically also been an increase in the image acquisition rate, and scanners with gantry 
rotation rates of up to 4 Hz are now readily available. Combining this fast acquisition 
rate with contrast agents has enabled additional functional information to be acquired 
using CT. This technology was initially adopted in CT perfusion studies to assess blood 
flow to the brain in patients with suspected stroke. However, it has also been used in 
oncology to assess and track changes in tumour neovasculature (Perini et  al. 2008), 
allowing clinicians to evaluate tumour response to therapeutic agents.
CT contrast agents are a highly researched application of NPs and the results of these 
in  vitro/in vivo studies have been extensively reviewed in recent publications (Hahn 
et al. 2011; Shilo et al. 2012; Lee et al. 2013; Cole et al. 2015). Interest in NP contrast 
agents has been stimulated as a result of their flexibility, specificity and biocompatibility 
(Kim et al. 2010). As NPs can be formulated with a wide range of elements at their core, 
they can exploit high-Z elements, such as gold and platinum, which offer a desirable 
combination of strong absorption of x-rays and high density, providing superior con-
trast enhancement for lower concentrations of contrast agent. Due to their small size, 
NPs distribute rapidly and effectively throughout the circulatory system, enabling direct 
usage as vascular imaging agents or more specific targeting through conjugation to an 
appropriate targeting ligand. NPs also have increased clearance by the liver (Longmire 
et al. 2008), and therefore offer an alternative option for patients who cannot receive CT 
contrast due to the risk of nephrotoxicity. Finally, many in vivo studies have shown NPs 
to be biocompatible at concentrations which are relevant to imaging applications (Hain-
feld et al. 2006).
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In the oncology field, these benefits are further enhanced by NPs’ ability to penetrate 
the so-called ‘leaky vasculature’ formed in tumours due to the rapid proliferation of 
blood vessels via the enhanced permeability and retention effect (EPR). These rapidly 
growing vessels are permeable to nanometre-scale agents, allowing NPs to accumu-
late rapidly within tumour volumes, even when delivered intravenously. This may be 
enhanced by combining the NPs with a suitable targeting antibody or peptide to ena-
ble them to bind to the tumour cells and prolong the time spent within the tumour. In 
this way, tumour-specific contrast CT imaging can also be delivered, potentially offering 
superior tumour delineation.
A previous limitation of CT technology was its inability to discriminate between mate-
rials with similar attenuation coefficients for a single x-ray tube potential (kVp). This 
made it challenging to differentiate between contrast agents and physically dense tis-
sues, such as bone (Thorsten et al. 2007). The development of dual-energy CT has gone 
some way to address this limitation. This technology effectively acquires two images of 
a patient’s anatomy using x-ray photons with either a low or high kVp spectrum. Due 
to the variation in attenuation coefficient with x-ray energy for different materials, the 
reconstructed composite images are more sensitive to the chemical composition of 
materials within a patient, enabling higher contrast between dense tissues and con-
trast agents (Johnson et  al. 2007). Ongoing research into “spectral CT” detector tech-
nology may also enable similar discrimination of metal elements without the need for 
dual-energy acquisitions by differentiating the energy of the x-ray photons incident on 
its detector (Schlomka et  al. 2008). The enhancement in tissue discrimination offered 
using these technologies could be increased further through the use of NP-based con-
trast agents (Cormode et al. 2010).
MR imaging
Magnetic resonance imaging is an alternative imaging modality used regularly in oncol-
ogy diagnostic examinations as it is capable of generating 3D anatomical informa-
tion with superior soft tissue contrast compared to CT. The enhanced detail provided 
through the extensive range of advanced MRI acquisition protocols can enable clinicians 
to monitor the response of patients following their respective treatments. Nicolae et al. 
(2016) recently reviewed the application of advanced MR techniques to guide brachy-
therapy treatments and discussed how this enhanced guidance could be combined with 
NP agents to synergistically increase doses to cancerous tissue, whilst reducing the risk 
of radiation-induced side-effects. MRI functional diffusion maps have also been shown 
to provide early indications of brain tumour response to radiotherapy and chemotherapy 
treatments (Moffat et al. 2005). Functional diffusion maps have also been found to indi-
cate the response of prostate bone metastasis to antiandrogen therapy (Reischauer et al. 
2010).
Depending on the tissue of interest, magnetic resonance (MR) image contrast can also 
be further enhanced through the use of contrast agents. MRI contrast agents incorpo-
rate materials that influence local magnetic fields in their surrounding tissue, thus affect-
ing the nuclear relaxation times used to generate MR images. Superparamagnetic iron 
oxide nanoparticles (SPIONs) are already in clinical use as MR contrast agents for a 
range of anatomical sites including the bowel, liver/spleen (Sun et al. 2008) and prostate 
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(Coulter et al. 2015). However, the majority of MRI contrast agents are based on chelates 
of gadolinium. As will be discussed later, the high atomic number of gadolinium also has 
the potential to increase the radiosensitivity of surrounding tissues when immersed in 
an x-ray field and NPs that incorporate gadolinium have been proposed as theranostic 
agents (Sancey et  al. 2014). Gadolinium chelates have also been combined with gold-
based NPs creating the potential for a multimodality contrast agent that can be observed 
in both MR and CT images (Alric et al. 2008).
Radioisotope imaging
Whilst CT and MRI are gaining the capability of providing functional information, they 
are currently unable to provide the same diagnostic value as radioisotope imaging (e.g. 
PET) in identifying cancerous tissue. PET studies using the Fluorodeoxyglucose (18F-
FDG) radiotracer are commonly used in oncology investigations to identify potential 
cancerous tissues by highlighting regions of high metabolic activity. New radiotracers 
are under development and a number have been adopted clinically. One example is 
ligands of the prostate-specific membrane antigen (PSMA) which can be tagged with the 
positron-emitting 68Ga radioisotope (Afshar-Oromieh et al. 2013). Expression of PSMA 
in prostate cancer can inform clinicians of the tumour grade, pathological stage, or if it 
has developed castration resistance (Lütje et al. 2015). Recent in vitro studies have also 
demonstrated how coupling PSMA ligands to NP contrast agents can offer the facility to 
access this information using more readily available imaging modalities, such as CT and 
MRI (Wan-Chi Tse et al. 2015), whose image quality is not constrained by the limited 
spatial resolution inherent in PET images.
Radiomics
It has recently been highlighted that the information contained within digital oncology 
images is a resource yet to be fully exploited, leading to an emerging field of research 
called radiomics (Lambin et  al. 2012; Aerts et  al. 2014). Radiomics is the conversion 
of digital images into mineable high-dimensional data (Gillies et al. 2016), where over 
400 image features can be extracted from volumes of interest, including tumour shape, 
size and texture. These attributes can provide insight about a cancer’s phenotype, help-
ing to inform the clinician of the best form of treatment. Radiomics analysis has the 
potential to include complementary information to other diagnostics such as genomics, 
pathology and blood biomarkers (Lambin et al. 2012), allowing for an improvement in 
the specificity of diagnostic tests. Recent radiomic studies have identified intravascular 
contrast-related image biomarkers that have the potential to improve the prediction of 
xerostomia and sticky saliva after radiotherapy with contrast (van Dijk et al. 2016). There 
is therefore the potential that introducing NP contrast agents into the tumour environ-
ment could also allow radiomic analysis to extract additional information from patient 
images regarding NP uptake and distribution within the tumour, potentially providing 
further insight into the cancer’s phenotype. Access to this diagnostic information should 
allow clinicians to further personally tailor each patient’s cancer treatment to ensure the 
optimum outcome.
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Radiation therapy
One application of nanotechnology that is undergoing extensive research is its incor-
poration into radiation therapy treatments (Wang and Tepper 2014). Results of in vivo 
studies have shown that radiosensitising NPs have the potential to increase the radiation 
dose to tumour cells, enhancing tumour control whilst sparing surrounding normal tis-
sue and thus maximising the therapeutic ratio (Hainfeld et al. 2004). High-Z NPs, par-
ticularly gold NPs, were originally considered as radiation contrast agents due to their 
high atomic number. It was believed that by combining these agents with kV x-rays, the 
strong photoelectric absorption of x-rays by high-Z elements would increase the dose 
deposited in the target volume, and in turn lead to an increase in cell death. Whilst early 
in vivo work in this area saw successful radiosensitisation (Hainfeld et al. 2008), subse-
quent Monte Carlo comparisons have suggested that the increase in physical dose does 
not fully explain the observed radiosensitisation (Butterworth et  al. 2012), which was 
often significantly larger than the physical dose increase.
In vitro and Monte Carlo studies have reported that the factors which impact NP radi-
osensitisation are yet to be fully understood (Jain et al. 2011; McMahon et al. 2011), and 
are therefore the subject of intensive research, but are believed to involve both physi-
cal and biological effects. Physically, in addition to increasing total absorption, the pho-
toelectric effect typically leads to the ejection of an inner shell electron from an atom. 
This leaves a highly excited ion, which will proceed to release a large number of lower 
energy x-rays and Auger electrons. These particles deposit their energy across very short 
ranges, leading to highly localised damage similar to that seen in hadron therapy (Coul-
ter et al. 2013). Such localised effects are known to drive greater biological damage than 
the uniform exposure delivered by x-rays, potentially contributing to their greater effec-
tiveness. In addition, certain NP preparations have been seen to drive additional bio-
logical effects, such as mitochondrial stress or the production of reactive oxygen species, 
which may contribute a degree of biological sensitisation to tumour cells, in addition to 
their impacts on the physical dose distribution.
Treatment planning
The application of external beam radiotherapy to treat cancer has evolved immensely 
in the past two decades. Increased access to volumetric images of a patient’s internal 
anatomy has enabled delineation of soft tissue anatomy and supported the development 
of more conformal treatment techniques such as Intensity Modulated Radiation Therapy 
(IMRT) and Volumetric Modulated Arc Therapy (VMAT). The reduction in dose to crit-
ical normal tissues afforded by IMRT has gradually led to a shift from conventional 2 Gy 
fractionation schedules for some treatment sites to take advantage of the radiobiologi-
cal response exhibited by both tumours and surrounding normal tissue. An example of 
this is Stereotactic ABlative Radiotherapy (SABR) where IMRT/VMAT is used to deliver 
high radiation doses in a small number of treatment fractions (Chang and Timmerman 
2007).
The ability to deliver radiotherapy treatments with a higher degree of conformity is 
also allowing clinicians to use this modality to treat diseases previously managed via 
other means. Oligometastatic disease [metastatic cancer which has spread to a limited 
number of sites (Weichselbaum and Hellman 2011)] is an example of this. Treatment of 
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oligometastases with SABR presents an option for patients who are unsuitable for inva-
sive surgery (Hoyer et al. 2006). The use of NP contrast agents in diagnostic tests has 
the potential to help identify patients with oligometastases who would benefit from this 
localised radiation therapy.
Despite their superior soft tissue contrast, MR images are subject to image distortion. 
MRI pixel values are also closely correlated with tissue proton density, which cannot be 
directly translated into electron densities for simulation of x-ray interaction. As a result, 
CT images are typically used to plan patient treatments as they are subject to less image 
artefact and contain accurate electron density information for modelling MV photon 
interactions. Unfortunately, despite the anatomical information provided by CT, deline-
ation uncertainty is still a key source of uncertainty in radiotherapy (van Herk 2004). 
Whilst peer review has been highlighted as a means to reduce this uncertainty (Marks 
et al. 2013), lack of image contrast remains a limiting factor in determining the bound-
ary of a cancerous volume. Contrast agents can also improve target delineation but may 
influence the accuracy of treatment planning algorithms (Ramm et al. 2001). However, 
the use of dual-energy CT may reduce the dosimetric impact of this influence (Yam-
ada et  al. 2014) and allow the benefits for NP contrast agents to be exploited further. 
Additionally, if NP contrast agents can be functionalised to highlight tumour burden and 
hypoxia regions they may offer the opportunity for a different type of conformal radio-
therapy: dose painting (Ling et al. 2000). This modality introduces the concept of a “bio-
logical target volume”, a subvolume of a tumour target that can be highlighted through 
functional imaging modalities as having a reduced radiosensitivity. The premise of dose 
painting is that the treatment outcome may be improved by delivering a larger radiation 
dose to this subvolume. It is important to highlight that there is debate over the effective-
ness of these highly conformal treatments due to other processes (such as the bystander 
effect), which may act to blur the biological effect that the dose distribution has on cells 
(McMahon et al. 2015).
The algorithms used by treatment planning systems (TPSs) to tailor treatment fields to 
a patient’s individual anatomy and simulate the resultant dose distribution, have evolved 
at a similar rate to the treatment techniques that they model. With each evolution of the 
algorithms, additional physical processes are incorporated into the models, improving 
agreement between the simulated dose distributions and the current gold standard—
Monte Carlo simulations (Han et al. 2011). However, the majority of modern commer-
cial TPSs primarily only consider Compton scattering interactions and apply density 
scaling to correct for inhomogeneities in a patient’s anatomy. Introducing metallic NPs 
into a patient’s treatment also results in the need for Monte Carlo based algorithms to 
accurately model the deposition of physical dose within a patient (Schuemann et  al. 
2016). Furthermore, for the results of these calculations to be meaningful, consistent NP 
uptake throughout a patient’s treatment is critical, and a stringent preparation protocol 
would be required.
The need for biological optimisation within treatment planning algorithms was high-
lighted following the introduction of IMRT (Brahme 2001) and has been incorporated 
into hadron therapy treatment plans to account for their increased linear energy trans-
fer properties (Krämer and Scholz 2000). Biological optimisation takes into account 
the radiosensitivity of the target volume and surrounding organs at risk to generate 
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treatment plans with the optimum therapeutic ratio. Similar optimisation would be 
essential when employing NP radiosensitisation and would require accurate characteri-
sation of NP interaction with the x-ray spectrum of the irradiation field as a function of 
nanoparticle material, size and concentration (Schuemann et al. 2016).
Treatment delivery
The introduction of highly conformal techniques has increased the need for pre-treat-
ment verification imaging to confirm accurate positioning of the patient. As a result, 
image-guided radiotherapy (IGRT) has developed at a similar pace to IMRT techniques. 
Most manufacturers now offer linacs with kV-based on-board imagers, capable of gener-
ating high-contrast planar images, as well as volumetric Cone Beam CT (CBCT) images 
of the patient’s internal anatomy at the time of treatment. Whilst CBCT images provide 
invaluable volumetric information, the acquisition method has a number of image qual-
ity limitations compared to their diagnostic CT counterparts (Srinivasan et  al. 2014). 
Studies using IGRT with contrast-enhanced CBCTs have reported an improvement in 
target localisation accuracy of liver tumours in patients who have undergone chemoem-
bolization using iodine-based Lipiodol contrast agent (Yue et al. 2012). However, further 
consideration needs to be given concerning administering contrast agents (including 
NPs) during treatment, including the implementation of strict administration protocols 
to enable consistent contrast distribution and accurate dose simulation.
The volumetric information contained within CBCT images can also be of additional 
benefit after a patient’s treatment to determine the dose the patient actually received 
(Hatton et al. 2011). The range of IGRT solutions currently available (such as CBCT, pla-
nar imaging and fluoroscopy systems) may also allow for the evaluation of changes in 
NP uptake and provide a means to monitor patient response to their treatment. With 
the rapid adoption of IGRT, there is discussion about incorporating the imaging dose 
into a patient’s radiotherapy prescription (Hyland et al. 2014; Alaei and Spezi 2015). If 
NPs were also to be introduced into the clinical environment then the imaging dose may 
become more clinically significant through their inherent kV dose-enhancement proper-
ties (Butterworth et al. 2012).
As mentioned previously, the main benefit to using NPs during treatment is the poten-
tial dose enhancement that results from the interaction of the MV treatment field with 
the NPs. With targeted uptake of NPs, there is the potential to increase the dose to 
the tumour whilst maintaining or reducing dose to surrounding normal tissue. This is 
particularly relevant to SABR treatments, where a single geometric miss in the hypof-
ractionated treatment schedule can result in a reduction in tumour control and/or an 
increase in toxicity effects. There is also a trend towards the increased use of flatten-
ing filter free (FFF) fields to deliver SABR treatments due to their significantly higher 
dose rates. Whilst previous concerns regarding synergistic biological effects with these 
higher instantaneous dose rates have so far proved to be unfounded (King et al. 2013), 
in vitro studies have indicated that NP interaction with the softer photon spectrum asso-
ciated with FFF fields may enhance their dose deposition properties further (Detappe 
et  al. 2016). Further study is therefore required to fully evaluate the possible physical 
and biological enhancements that  can result from combining FFF fields with NPs. An 
intriguing potential alternative application of nanoparticles in radiotherapy is as vectors 
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for radiation protection agents (Schweitzer et al. 2010). An in vivo study with mice dem-
onstrated that intravenous delivery of melanin-coated NPs reduced bone marrow tox-
icity during external beam radiotherapy without affecting tumour control (Schweitzer 
et al. 2010).
Emerging technologies
In light of the benefits that IGRT has brought to radiotherapy treatments, manufactur-
ers are investigating methods to provide additional imaging information at the time of 
treatment. To take advantage of the superior soft tissue contrast, MRI devices have been 
combined with Cobalt sources and MRI-guided linac systems are also in development 
(Oelfke 2015). A PET-based linac system is also under development with the premise 
that the tumour target essentially guides the treatment delivery (Fan et  al. 2012; Yang 
et al. 2014). These combined treatment/imaging modalities provide additional avenues 
of research to determine how the diagnostic and therapeutic merits of nanotechnology 
can be used to further enhance their therapeutic benefit. Such studies are of importance 
as little is known about the potential dosimetric effects of introducing NPs into overlap-
ping magnetic and x-ray fields.
The number of radiotherapy centres using beams of protons or heavy ions (hadrons) 
to treat tumours is rapidly increasing, with approximately 70 clinically active cen-
tres worldwide and another 50 centres being built or planned (PTCOG 2016a, b). The 
dose deposition characteristics of hadrons make them a very attractive choice of radia-
tion therapy. Hadrons have a low entrance dose and deposit the majority of their dose 
in a well-defined Bragg peak, determined by particle energy, with rapid dose fall-off 
subsequent to this. This generates dose distributions with superior conformity around 
the target volume compared to photons, which is particularly important with tumours 
that are directly adjacent to a radiosensitive organ. Hadrons also cause highly localised 
damage on the sub-cellular scale resulting in enhanced radiobiological effectiveness. 
Monte Carlo simulations have indicated that metal NPs can also provide dose enhance-
ment during hadron therapy (Lin et al. 2014). This enhancement has been confirmed in 
in vitro studies using He2+ or C6+ beams combined with gadolinium-based NPs (Porcel 
et al. 2014), where it was observed that the dose enhancement stemmed from the activa-
tion of early nano- and sub-nanosized processes in the cytoplasm, far from the nucleus.
Radiation therapy is also commonly combined with other well-established treatment 
modalities (such as chemotherapy) to enhance treatment outcome (Harrington et  al. 
2011). The use of NPs to deliver chemotherapeutic agents has been extensively reviewed 
(Brigger et al. 2002; Wang et al. 2012). As with their application in radiotherapy, one of 
the main advantages to employing NPs as chemotherapy vectors is the improved tar-
geting potential. Clinical translation of this localisation attribute has been investigated 
in clinical chemotherapy studies using a number of chemotherapy agents which were 
recently reviewed by Wang and Tepper (2014). There is also the potential to use NPs as 
chemoradiotherapy enhancing agents for concurrent therapies, where increased uptake 
in the tumour can enhance tumour control whilst reducing unintentional side-effects 
caused by damage to normal tissues (Wang and Tepper 2014). NPs can also be employed 
to build upon the success of recent radionuclide therapies, such as clinical trials that 
employed radium-223 (Hoskin et  al. 2014). With radioisotope-tagged functionalised 
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NPs, there is the potential to translate this success to other metastatic diseases (Barreto 
et al. 2011).
Limitations and challenges
As highlighted throughout the text, there are a number of challenges that must be over-
come before nanotechnology can be introduced into routine clinical practice in radia-
tion oncology departments. Chief amongst these is the development of clinical trials 
to evaluate the efficacy of NP-mediated diagnosis and/or treatment and to quantify the 
clinical benefit to patients. However, before clinical trials can be formulated a number of 
other limitations must be addressed.
To be clinically applicable, NPs must fulfil a very stringent set of criteria. These include 
biocompatibility, to reduce the risk of treatment side-effects; desirable pharmacokinetic 
properties, providing both high target specificity and good dispersion throughout the 
target volume; and efficacy in driving the desired effect in target cells (whether imaging- 
or therapy-related). In vitro and in vivo studies of these properties have shown that they 
are not easy to predict from individual particle characteristics. Rather, they are the result 
of a complex interplay between particle size, shape, material and coating, amongst other 
factors. Because of this interplay, piecewise optimisation of NP properties is not likely to 
be feasible, but particles must be subjected to comprehensive preclinical studies in vitro 
and in vivo considering all of these effects before being translated into clinical studies 
(Shuemann et al. 2016).
There also remains the significant challenge of manufacturing NPs on a practical scale. 
Most studies make use of either in-house NP preparations, or commercial particles pro-
duced on a scale suitable for laboratory experiments. Many of these preparations are 
often expensive—with bare unconjugated nanoparticles costing on the order of $10,000/
gram of gold, and bespoke functionalised particles having significantly greater effective 
costs. The effective scalability of novel nanoparticles therefore requires consideration 
when developing new approaches. However, demonstration of clinical proof of principal 
should increase interest and competition from large pharmacological companies.
Finally, effective modelling of the physics of NP interactions remains a pressing chal-
lenge. The introduction of high-Z materials into tissue is currently poorly incorporated 
by most TPS, and more robust, validated physics models are needed to ensure that the 
quality of radiotherapy plans are not reduced through the introduction of nanoparticles 
as part of treatment planning.
Conclusions
New technologies are rapidly being introduced into the radiation oncology environment 
with many technologies offering features that are yet to be fully exploited. In the emerg-
ing era of increased personalisation of oncology treatments, nanoparticles can provide 
an extremely useful tool in every stage of a patient’s radiotherapy experience from diag-
nosis, to treatment and subsequent follow-up monitoring. As this technology begins to 
be introduced into the clinical environment, close collaboration between academic and 
clinical staff is essential to identify potential challenges and opportunities and ensure 
that this promising technology provides the maximum benefit to patients.
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